The GPP Forum
The generalized pustular psoriasis (GPP) Forum - a multistakeholder event collaborating for a new vision for people living with GPP
Search
Something learnt
We know that to really thrive as a company, we have to help our teams to continue to grow in their careers. Here are some of things they have learnt at work.
Rewards and recognition
There are achievements and occasions that demand recognition. We go out of way to give employees tangible rewards and more for business milestones.
Learning and development
We help people grow professionally by maximizing our talent and giving them room to evolve within the company.
Smart scanners to spot fleas and ticks on your pet
How to identify fleas and ticks? With technology, vets can now spot pet parasites with high-definition videos in real time.
Rabies prevention local action partnering organizations
Global rabies prevention needs local action. Together with partnering organizations, we’re using pilot projects to find the right approach.
Emmanuelle leads a team of scientists
Want to work for a company that allows you to grow your career? Emmanuelle talks about her job journey at Boehringer Ingelheim.
Laura loves her diverse career
Laura loves her diverse career at Boehringer Ingelheim. For more talent insights, visit our Careers Page.
Redefining mental health to enable people to thrive
At Boehringer Ingelheim, we aim to develop targeted treatment approaches that address specific symptoms in people living with mental illness.
collaboration-proxygen-molecular-glue-degraders
Boehringer Ingelheim collaborates with Proxygen to explore molecular glue degraders – a novel approach to fight cancer.
Partnership-with-clicktherapeutics
Boehringer Ingelheim collaborates with Click Therapeutics on prescription-based digital therapeutic to potentially aid in the treatment of schizophrenia
Partnering Approach Video 2023
Our Animal Health Business Development & Licensing team talks about Boehringer Ingelheim’s unique partnering approach and spirit of collaboration.
Zongertinib (BI 1810631): HER2 Tyrosine Kinase Inhibitor (TKI) | NSCLC
Zongertinib (BI 1810631): HER2 Tyrosine Kinase Inhibitor (TKI) | NSCLC
Nagoya Protocol
At Boehringer Ingelheim, environmental consciousness and protection are priorities in everything we do.
Covid19 relief program Ghana Cowtribe parasiticides
Boehringer Ingelheim and Cowtribe are kicking off a vital relief initiative in Ghana.
Improving Access to Healthcare
According to the UN Sustainable Development Goals, almost half of the global population is not covered by essential health services.
HER2 TKI, Zongertinib
HER2 TKI, Zongertinib
Eyes on Retina. The Podcast
Hear from experts and people living with retinal diseases such as wet age-related macular degeneration (AMD), stargardt disease and diabetic retinopathy.
Launch of Frontline flagship store on Tmall
Boehringer Ingelheim launches Frontline flagship store on Tmall to sell selling full range of pet parasiticides.
COVID-19 Material donations in Germany
Life forward - Boehringer Ingelheim company brand
Life forward - Boehringer Ingelheim unveils its evolved company brand
Schizophrenia in real life
Discover the reality of life with schizophrenia through the stories of people who are breaking down the stigma of living with a serious mental illness.
empulse-trial-benefit-acute-heart-failure
Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
From social worker to joining the pharmaceutical industry
Patient centricity: How Miyuki Ono contributes to our diverse workforce with her experience as a social worker and helps patients in Japan
Boehringer Ingelheim acquires Nerio Therapeutics
Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline by adding an innovative preclinical program with the acquisition of Nerio Therapeutics